Profound MedicalTSX:PRN +7.28%68 Days Payable is 112.63 as of Mar. 2026, which is 63% below its 10-year median of 305.57. GuruFocus rates TSX:PRN with a GF Score™ of 68/100 and a GF Value™ of C$20.37 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, Profound Medical ranks better than 59.75% on this metric.
The historical rank and industry rank for Profound Medical's Days Payable or its related term are showing as below:
TSX:PRN'
s Days Payable Range Over the Past 10 Years
Min: 86.6 Med: 305.57 Max: 937.87
Current: 86.6
During the past 12 years, Profound Medical's highest Days Payable was 937.87. The lowest was 86.60. And the median was 305.57.
TSX:PRN's Days Payable is ranked better than 59.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TSX:PRN: 86.60
Profound Medical's Days Payable
declined
from Mar. 2025 (139.85) to Mar. 2026 (112.63).
It may suggest that Profound Medicalaccelerated paying its suppliers.
Profound Medical Days Payable Related Terms
Profound Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Profound Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Profound Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Profound Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (TSX:PRN) has a Days Payable of 112.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Profound Medical and its competitors. This is 63% below median its historical median of 305.57. Over the past decade, Profound Medical's Days Payable has ranged from 86.60 to 937.87. According to the industry distribution chart, Profound Medical ranks #320 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 40.3%.
Is Profound Medical's Days Payable too high?
Profound Medical's current Days Payable of 112.63 is 63% below median its 10-year median of 305.57. Over the past 10 years, this metric has ranged from a low of 86.60 to a high of 937.87. The Medical Devices & Instruments industry median Days Payable is 68.07. Profound Medical's value of 112.63 is 65.5% above this industry median. Based on the distribution chart, Profound Medical ranks #320 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Profound Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #320 out of 795 companies for Days Payable. This puts Profound Medical in the upper half of its industry. The industry median Days Payable is 68.07. Profound Medical's value of 112.63 is 65.5% above this benchmark. Historically, Profound Medical's own Days Payable has ranged from 86.60 to 937.87 over the past decade. While the company's 10-year median is 305.57 vs. the industry median of 68.07, Profound Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Days Payable of 112.63 is 65.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Days Payable is 112.63, which is 63% below median its own 10-year median of 305.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$20.37, compared to a current price of C$10.46 — trading 48.6% below its estimated fair value. The current Days Payable is 112.63, which is 63% below median its 10-year median of 305.57 and 65.5% above the Medical Devices & Instruments industry median of 68.07. Profound Medical's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current Days Payable is 112.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (TSX:PRN) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of C$10.46 is trading 48.6% below its estimated GF Value™ of C$20.37.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for TSX:PRN:
Days Payable: 112.63 (63% below median its 10-year median of 305.57)
GF Value™: C$20.37 vs. price of C$10.46 (48.6% below fair value)
Industry Position: 65.5% above the Medical Devices & Instruments median (#320 of 795)
No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
68GF Score
Get the complete analysis for TSX:PRN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRN has been successfully added to your 
